// App-Quantinova.ai

P466 : Hypogonadal patients with Crohn's disease benefit from treatment with testosterone - data from an ongoing, long-term, observational registry study

Researchers

Presenter

  • M. Nasser

Principal Investigators

  • G. Doros

  • W. Kurtz

  • A. Haider

  • L. Gooren

Medical Centers

  • Private Urology Practice, Bremerhaven, Germany

  • Klinikum Bremerhaven, Dpt. of Internal Medicine, Bremerhaven, Germany

  • VU medical Center, Dpt. of Internal Medicine, Endocrine section, Amsterdam, Netherlands

  • University of Aleppo, Dpt. of Gastroenterology, Aleppo, Syrian Arab Republic

  • Boston University School of Public Health, Dpt. of Epidemiology and Statistics, Boston, United States

Locations

  • United States

  • Germany

  • Syria

  • Netherlands

Companies

  • Bayer

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

  • Crohn's disease

Biomarkers

  • High sensitivity C-reactive protein

  • Twist-related protein 2

Drug/Treatment

  • LPCN 1111

  • Hydroxyzine

Outcome

  • Unknown

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved